Australian Court Says Genes Are Patentable

from the sweat-of-the-brow? dept

While the US Supreme Court will soon be weighing in on whether or not genes are patentable in the Myriad Genetics case, we've also been following a similar case in Australia. There, a bunch of cancer patients took Myriad to court, arguing that the patent on BRCA1 is invalid (this same gene is part of the US case). Unfortunately, the court has decided that genes are, in fact, patentable if they've been isolated. This is always the key point of contention with gene patent supporters. They claim that it's the fact that they can separate the gene that makes their work patentable. In some ways this is an odd sort of "sweat of the brow" argument for patents -- and here, the judge is buying the argument completely. He says that patenting genes in the human body would be a problem... but isolating them magically makes it a different story.

There is no doubt that naturally occurring DNA and RNA as they exist inside the cells of the human body cannot be the subject of a valid patent. However, the disputed claims do not cover naturally occurring DNA and RNA as they exist inside such cells. The disputed claims extend only to naturally occurring DNA and RNA which have been extracted from cells obtained from the human body and purged of other biological materials with which they were associated.

This still seems ridiculous to me. If others figure out how to get an isolated gene as well, why should that be subject to a patent? Hopefully this is not a preview of the US Supreme Court's upcoming ruling.

Filed Under: australia, brca1, breast cancer, cancer, genes, patents
Companies: myriad, myriad genetics

Myriad Offers To Give Up Its Infamous Gene Patent In Australia

from the but-why? dept

We've been covering the legal fight over the patenting of genes for quite some time, and there's been an interesting (if odd) development, concerning the BRCA patents, held by Myriad Genetics, that have been the key patents in the legal battle. Back in March, a district court judge famously held that genes were unpatentable, and said that the BRCA patents (covering genes related to breast cancer) were invalid. A few months later, it was interesting to see a very similar case filed in Australia, also against Myrida and over BRCA patents.

However, as Glyn Moody alerts us, there's been a slightly surprising development down in Australia, as Myriad has offered to surrender the patent to the people of Australia. Specifically, Myriad sent a letter, stating:

"Myriad wishes to gift Australian Patent No 686004 [the '004 Patent] to the people of Australia."

This is, certainly, an odd turn of events, and no one's quite sure why. Some have suggested that it's to help with the US case by avoiding another ruling against such patents in Australia -- but as the article notes, that makes little sense. The patent systems are different in the US and Australia and have little, if any, impact on one another. My guess (and it's a guess) is that Myriad realized that this one particular patent is weak, and doesn't want it to be a part of any lawsuit that could impact its other patents or the wider ability to patent genes, and is thus offering it up to get it out of the lawsuit. That's an admittedly cynical take, but I'm having trouble coming up with other possibilities that make sense. Perhaps any readers more familiar with the Australian patent system can fill us in on why they think this is happening.

Filed Under: australia, brca, gene patents
Companies: myriad